S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
Log in

Nyrada Inc. (NYR.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: A$0.16
52-Week Range N/A
Volume65,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company was founded in 2017 and is based in Gordon, Australia.


Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Phone61 2 9053 1990



Sales & Book Value

Annual Sales$1.13 million
Book ValueA$0.05 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive NYR News and Ratings via Email

Sign-up to receive the latest news and ratings for NYR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nyrada Inc. (NYR.AX) (ASX:NYR) Frequently Asked Questions

What stocks does MarketBeat like better than Nyrada Inc. (NYR.AX)?

Wall Street analysts have given Nyrada Inc. (NYR.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nyrada Inc. (NYR.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Nyrada Inc. (NYR.AX)'s key competitors?

Who are Nyrada Inc. (NYR.AX)'s key executives?

Nyrada Inc. (NYR.AX)'s management team includes the following people:
  • Mr. James Bonnar, Chief Exec. Officer
  • Mr. Cameron Jones C.A., Chief Financial Officer
  • Mr. Benjamin Evison Ph.D., Chief Scientific Officer
  • Mr. Mark Waring B.Sc., P.M.P., Sr. VP of US Operations
  • Mr. David James Franks B.Ec, BEc, CA, F Fin, JP., Company Sec. (Age 51)

What is Nyrada Inc. (NYR.AX)'s stock symbol?

Nyrada Inc. (NYR.AX) trades on the ASX under the ticker symbol "NYR."

How big of a company is Nyrada Inc. (NYR.AX)?

Nyrada Inc. (NYR.AX) has a market capitalization of $0.00 and generates $1.13 million in revenue each year.

What is Nyrada Inc. (NYR.AX)'s official website?

The official website for Nyrada Inc. (NYR.AX) is www.nyrada.com.

How can I contact Nyrada Inc. (NYR.AX)?

The company can be reached via phone at 61 2 9053 1990.

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.